Shandong Sanyuan Biotechnology Co. Ltd. Class A

Shandong Sanyuan Biotechnology Co. Ltd. Class A

SSZSE:301206
21.76
CNY
+0.05
(+0.23%)
0.39EPS
64.47P/E
5.06BMarket Cap
Apr 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.64
0.78
1.05
0.68
0.85
1.98
2.18
3.44
7.36
3.38
2.5
3.53
3.27
3.89
Basic EPS, GAAP
0.01
0.02
0.05
0.11
0.13
0.47
0.62
1.02
2.35
0.82
0.28
0.52
0.46
0.39
Free Cash Flow per Basic Share
0.08
-0.42
- -
0.08
-0.19
0.11
0.04
0.29
0.91
-0.79
-0.33
-0.77
-0.89
- -
Dividend per Share
0.01
0.03
0.01
- -
0.03
0.03
0.02
0.31
- -
0.68
0.72
0.4
1.75
0.55
Book Value per Share
0.36
0.36
0.56
1.09
1.59
2.46
1.53
2.24
4.59
22.84
22.41
22.2
20.95
20.5
Tangible Book Value per Share
0.34
0.17
0.31
0.86
1.36
2.24
1.39
2.11
4.38
22.6
22.18
21.97
20.58
20.15
Basic Weighted Avg Shares
30
26
38
131
141
147
219
228
228
200
200
202
199
200
Sales/Revenue/Turnover
19
20
40
89
120
291
477
783
1,675
675
500
713
650
778
Operating Margin (%)
3.23
4.14
5.22
16.74
18.57
26.64
36.28
36.09
37.32
7.17
-11.61
1.4
4.64
4.82
Depreciation Expense
1
1
1
2
3
7
11
17
26
39
60
66
74
- -
Net Income, GAAP
- -
1
2
14
19
69
136
233
535
164
56
105
91
78
Effective Tax Rate (%)
- -
- -
- -
9.39
14.65
13.17
13.81
13.91
13.63
11.02
4.82
18.14
13.4
11.41
Profit Margin (%)
1.85
2.57
5.08
15.68
15.77
23.59
28.59
29.7
31.96
24.25
11.21
14.72
14.07
9.98
Working Capital
10
-2
-1
30
20
29
70
120
241
462
98
3,144
2,046
1,617
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
26
27
41
80
116
180
348
510
1,045
4,621
4,535
4,491
4,239
4,148
Return on Invested Capital (%)
- -
0.81
5.27
21.07
19.02
45.22
50.77
54.2
68.46
5.84
1.22
2.32
2.08
1.83
Return on Capital (%)
- -
4.14
6.88
22.29
19.31
46.46
51.66
54.21
68.85
5.78
1.22
2.33
2.1
1.84
Return on Common Equity (%)
- -
1.96
6.01
23.1
19.31
46.46
51.66
54.21
68.85
5.78
1.22
2.33
2.09
1.84

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
202
202
202
Market Capitalization
5,234
4,498
5,060

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,397
1,688
1,784
Cash, Cash Equivalents & STI
1,132
1,307
1,431
Accounts Receivable, Net
96
77
66
Inventories
149
202
180
Total Current Liabilities
132
233
167
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
77.3%
87.72%
-5.61%
Free Cash Flow
1,470.25%
26.38%
13.46%
Net Income, GAAP
112.23%
13.91%
-12.9%
Sales/Revenue/Turnover
48.98%
12.41%
-8.89%
Total Cash Common Dividend
- -
2,860,574.79%
330.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
192
185
138
198
713
2025
150
168
- -
173
650
2026
225
204
176
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.14
0.14
0.12
0.52
2025
0.12
0.16
- -
0.12
0.46
2026
0.13
0.12
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.15
0.01
0.4
2025
0.24
0.95
- -
0.55
1.75
2026
- -
- -
- -
- -
- -

Company Description

CEO
Bao Hua Cheng
Full Time Employees
441
Sector
Process industries
Industry
Chemicals: major diversified
Address
No.89, Zhangfu Road Binzhou SD China 256600
IPO Date
Feb 10, 2022
Business
Shandong Sanyuan Biotechnology Co., Ltd. (301206.SZ) manufactures and markets functional sugar alcohols and compound sweeteners, primarily erythritol, allulose, high-purity steviol glycosides such as rebaudioside M, and blended products including momordica grosvenori compound sugar, stevia compound sugar, and sucralose compound sugar; these are applied in table sugar, flavored sugar, beverages, candy, chocolate, baked goods, health foods, medical supplies, cosmetics, and chemical products. Founded in 2007 and headquartered in Binzhou, Shandong Province, China, the company operates a biological fermentation-based production process with an annual erythritol capacity of 5,000 tons and exports to Europe, the United States, East Asia, Southeast Asia, Australia, New Zealand, and Africa. In 2024, the company completed a CNY 100 million share repurchase program, repurchasing 2.3257 million shares by July 2025, and announced cash dividends for the third quarter of 2025 at an upcoming EGM; its allulose production license remains in process, supporting expansion into rare monosaccharides with properties akin to sucrose but nearly zero calories.